Figure 2
Activation of coagulation in sickle cell mice. (A) Plasma TAT levels in WT (open bar; n = 6) and BERK (filled bar; n = 16) mice (both on a similar mixed genetic background). *P < .05. (B) Plasma TAT levels in WTBM (open bar) or BERKBM (filled bar) mice injected with either a rat anti–mouse TF (n = 5 for WTBM; n = 14 for BERKBM) or control rat IgG antibodies (n = 8 for WTBM; n = 14 for BERKBM). (C) Plasma TAT levels in TWAA (open bar) or TWSS (filled bar) mice injected with either a rat anti–mouse TF (n = 6 for TWAA; n = 7 for TWSS) or control rat IgG antibodies (n = 7 for TWAA; n = 11 for TWSS). Asterisks directly above the bars indicate statistically significant difference compared with WTBM or TWAA controls within the same treatment: **P < .01; and ***P < .001.

Activation of coagulation in sickle cell mice. (A) Plasma TAT levels in WT (open bar; n = 6) and BERK (filled bar; n = 16) mice (both on a similar mixed genetic background). *P < .05. (B) Plasma TAT levels in WTBM (open bar) or BERKBM (filled bar) mice injected with either a rat anti–mouse TF (n = 5 for WTBM; n = 14 for BERKBM) or control rat IgG antibodies (n = 8 for WTBM; n = 14 for BERKBM). (C) Plasma TAT levels in TWAA (open bar) or TWSS (filled bar) mice injected with either a rat anti–mouse TF (n = 6 for TWAA; n = 7 for TWSS) or control rat IgG antibodies (n = 7 for TWAA; n = 11 for TWSS). Asterisks directly above the bars indicate statistically significant difference compared with WTBM or TWAA controls within the same treatment: **P < .01; and ***P < .001.

Close Modal

or Create an Account

Close Modal
Close Modal